Boston Scientific

Marlborough, Massachusetts, United States · Biotechnology, Health Care, Manufacturing

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and co

Key facts

Headquarters: Marlborough, Massachusetts, United States
Employees: 45,000
Industries: Biotechnology, Health Care, Manufacturing
Status: Public (BSX)
Website: bostonscientific.com
LinkedIn: Company page

Recent activity at Boston Scientific

Oct 07, 2026: Boston Scientific Appoints Joseph M. Fitzgerald as Chief Operating Officer
Oct 07, 2026: SEC 8-K (5.02): On October 7, 2026, Boston Scientific Corporation announced the promotion of Joe Fitzgerald to Executive Vice President and Chief Operating Officer, effective January 1, 2027. Mr. Fitzgerald has been with the company since 1990 and has held multiple leadership positions, most recently as Executive Vice President and Group President, Cardiovascular. His compensation package includes an annual base salary of $1,050,000, eligibility for an annual bonus with an incentive target of 110% of his base salary, and a $7 million equity award for 2027. This equity will consist of stock options and restricted stock units, vesting at 25% per year, demonstrating the company's commitment to his leadership in driving the Cardiovascular segment forward.
Sep 21, 2026: SEC 8-K (5.02): On September 21, 2026, Arthur C. Butcher communicated his decision to retire from his position as Executive Vice President and Group President for MedSurg and Asia Pacific at Boston Scientific Corporation, effective January 1, 2027. Following his retirement, Mr. Butcher will continue to serve as a senior advisor until February 26, 2027, while receiving a base salary during this advisory period. This transition may impact leadership structure and strategic direction within the MedSurg and Asia Pacific divisions of the company.
Sep 01, 2026: Boston Scientific Announces Strategic Investment To Acquire Majority Stake Of Acotec Scientific Holdings Limited
Aug 26, 2026: SEC 8-K (8.01): On August 25, 2026, Boston Scientific Corporation reported a cybersecurity incident that has caused a significant global disruption to its operations. The company activated its incident response protocols and engaged third-party cybersecurity experts to investigate and contain the threat. This incident is expected to lead to ongoing disruptions and limited access to critical information systems and business applications, which may affect various operational aspects of the company. The cybersecurity event emphasizes the vulnerability of corporate IT systems and the potential ramifications for business continuity and operational efficiency.
Jul 29, 2026: SEC 8-K (2.02): On July 29, 2026, Boston Scientific Corporation announced its financial results for the second quarter ending June 30, 2026. The press release disclosed detailed performance metrics and highlights for the period, showcasing the company's revenue and profit figures, which are crucial for investors. Although specific financial amounts were not detailed in this excerpt, the announcement is significant as it informs stakeholders about the latest operational performance. This disclosure facilitates transparency and aids in investment decision-making regarding the company's stock.
Jul 27, 2026: SEC 8-K (2.05):
May 18, 2026: SEC 8-K (8.01): On May 18, 2026, Boston Scientific Corporation announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank for $2 billion of its common stock, as part of a broader $5 billion share repurchase authorization. The agreement allows the company to repurchase approximately 30.4 million shares based on the closing price of $52.68 per share on May 15, 2026. The total number of shares repurchased will be adjusted based on the volume-weighted average price during the ASR's term, with a final settlement expected by June 30, 2026. Following this transaction, Boston Scientific will have $3 billion remaining in its share repurchase authorization, indicating a robust return of capital strategy.
May 18, 2026: SEC 8-K (8.01): On May 15, 2026, Boston Scientific Corporation entered into an investment agreement with MiRus LLC, acquiring non-voting common equity interests constituting 33.75% of MiRus for $1.5 billion. This agreement includes an exclusive option to acquire all equity interests of a subsidiary of MiRus formed to commercialize the Siegel transcatheter aortic valve replacement system, with additional payments totaling $3.0 billion contingent upon MiRus achieving specific clinical and regulatory milestones. This strategic investment enables Boston Scientific to enhance its presence in the cardiovascular market, potentially leading to significant financial returns based on future sales of the TAVR System. The agreement reflects a strong commitment to innovation in medical devices and positions both companies for growth in a competitive landscape.
May 18, 2026: SEC 8-K (8.01): On May 18, 2026, Boston Scientific Corporation announced an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank for $2 billion to repurchase its common stock. This transaction is part of the company's authorization to repurchase up to $5 billion in shares. The ASR will allow the company to immediately receive common stock equivalent to 80% of the repurchase price, based on the closing share price of the common stock. This initiative is strategically aimed at enhancing shareholder value and reflects the company's ongoing commitment to returning capital to shareholders.

Leadership

Joseph M. Fitzgerald, Chief Operating Officer
Marine Lambert, Human Resources Business Partner Endobariatrics
Jon Monson, Chief Financial Officer
Dan Brennan, Chief Financial Officer
Angelo Auricchio, Chief Medical Officer
Mike Mahoney, Chairman
Madan Krishnan, Vice President

Verified email and direct lines for Boston Scientific’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Boston Scientific files 7 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Boston Scientific in the news

Companies similar to Boston Scientific

IEC Medical Systems · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
Becton Dickinson · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
Baxter International · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
Alcon Silver · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
Mindray · Biotechnology, Health Care, Manufacturing, Medical, Medical Device

About Boston Scientific: questions and answers

What does Boston Scientific do?

Where is Boston Scientific headquartered?

Boston Scientific is headquartered in Marlborough, Massachusetts, United States.

How many employees does Boston Scientific have?

Boston Scientific has about 45,000 employees.

Who leads Boston Scientific?

Madan Krishnan is a Vice President at Boston Scientific.

What is the latest news on Boston Scientific?

On Oct 07, 2026, Boston Scientific Appoints Joseph M. Fitzgerald as Chief Operating Officer

Is Boston Scientific a public company?

Yes. Boston Scientific is publicly traded under the ticker BSX.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy